GlassScriptPhysician profile
Leea Arsenault
NPI 1750642062
$4,129.42
in general payments reported to CMS, 2019-2025
33 companies · $769 in 2025
The $769 reported for 2025 was more than what 92% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $684 · 2022: $1,061 · 2023: $712 · 2024: $904 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,285 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,284.68 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $544.27 | 2021-2025 | Winlevi, Ilumya |
| Pfizer INC. | $406.61 | 2021-2025 | |
| Lilly USA, LLC | $402.14 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $330.77 | 2021-2025 | Dupixent, Libtayo |
| Abbvie INC. | $307.88 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $256.93 | 2023-2025 | |
| Genzyme Corporation | $230.85 | 2021-2025 | |
| Leo Pharma INC. | $226.40 | 2021-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $181.77 | 2023-2024 | Tremfya, Stelara, Remicade |
| Incyte Corporation | $167.84 | 2021-2025 | Opzelura |
| Organon LLC | $141.51 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $128.87 | 2022-2025 | Sotyktu |
| Amgen INC. | $107.85 | 2021-2023 | Otezla |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Ucb, INC. | $74.26 | 2021-2025 | Bimzelx |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $74.12 | 2021-2025 | Nemluvio, Epsolay, Oracea |
| Almirall LLC | $68.12 | 2021-2023 | Seysara |
| Strata Skin Sciences, INC. | $47.55 | 2024 | Xtrac |
| Dermavant Sciences, INC. | $41.43 | 2024 | Vtama |
| Convatec INC. | $33.31 | 2024 | |
| Paratek Pharmaceuticals, INC. | $32.42 | 2024 | Nuzyra |
| Verrica Pharmaceuticals INC. | $31.26 | 2024 | Ycanth |
| Arcutis Biotherapeutics, INC. | $28.12 | 2023-2025 | Zoryve |
| Organogenesis INC. | $25.28 | 2025 | Affinity |
| Genentech USA, INC. | $25.25 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.08 | 2024 | Cyltezo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.96 | 2024 | Cabtreo |
| Dermira, INC. | $15.60 | 2021 | |
| Vyne Pharmaceuticals INC. | $15.40 | 2021 | |
| Lnhc, INC | $13.48 | 2025 | Zelsuvmi |
| Epi Health, LLC | $12.99 | 2022 | |
| Mayne Pharma Commercial LLC | $12.79 | 2023 | |
| Biofrontera INC. | $10.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leea Arsenault listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.